Overindulging in rich foods while taking a drug like Wegovy or Zepbound can raise the risk of side effects like nausea and ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

Trials of semaglutide, the active ingredient in Ozempic and Wegovy, improve Alzheimer’s biomarkers but do not slow disease ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...